TOP >
News Release
- 2012.05.11
- Differences Between Consolidated Forecasts and Consolidated Results for the Fiscal Year Ended March 31, 2012
- 2012.05.08
- Daiichi Sankyo and Coherus Biosciences Establish Strategic Collaboration to Develop and Commercialize Biosimilar Candidates
- 2012.04.20
- Daiichi Sankyo Equity Transfer for Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., Ltd. in China
- 2012.04.17
- Daiichi Sankyo Launches RANMARK(R), a Treatment for Bone Complications Stemming from Multiple Myeloma and Bone Metastases from Solid Tumors
- 2012.03.29
- NGM and Daiichi Sankyo Collaborate to Discover and Develop Innovative Therapeutics for Diabetes
- 2012.03.23
- Daiichi Sankyo Files for Approval in Japan to Market AMG 162 (denosumab), a Treatment for Osteoporosis
- 2012.03.23
- Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan
- 2012.03.07
-
Daiichi Sankyo to Facilitate New Drug Discovery in 2012 through Collaborative Research and Grants
- 2012.03.06
- Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan
- 2012.03.02
- GSK and Daiichi Sankyo enter into strategic alliance to establish a Vaccine Joint Venture in Japan
- 2012.02.23
-
Daiichi Sankyo and Terumo Announce Agreement for Co-development of Intradermal Vaccine for Infectious Disease
- 2012.02.22
- Daiichi Sankyo Receives Approval in Japan for Additional Indication of Diagnogreen(R) Intravenous Injection
- 2012.02.20
- Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma
- 2012.01.26
- RANBAXY ANNOUNCES COURT FILING OF CONSENT DECREE WITH U.S. FOOD AND DRUG ADMINISTRATION
- 2012.01.18
- Daiichi Sankyo Receives Approval in Japan to Market RANMARK(R), a Treatment for Bone Complications Stemming from Multiple Myeloma and Bone Metastases from Solid Tumors
